~~<i id='057AFF46AE'><strike id='057AFF46AE'><tt id='057AFF46AE'><pre id='057AFF46AE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

author：knowledge 2025-09-30 01:03:18 - browse：15576

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Cassava reveals details — and problems — with Alzheimer's study

knowledge

focus

hotspot

explore

knowledge

focus

KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress might make insulin pumps more accessible to the blind

WHO may add ‘noma' to its list of neglected tropical diseases

First Opinion Podcast: How to protect health care in times of war

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

Wikipedia

knowledge

In age of alternative facts, a scholarly course on calling out crap

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Abbott's new heart device gets FDA advisory panel nod

Cancer drug shortages should be causing more outrage

Abbott's new heart device gets FDA advisory panel nod

Walensky prepares to leave CDC — and Congress — behind

Diversifying clinical trials isn't enough to close racial gaps: study

The cancer drug shortage isn’t new — and neither are the solutions

Chimpanzees, like humans and whales, get menopause: Study

focus

Testing for cancer recurrence creates a new limbo for patients

Medtronic CEO on promising devices for diabetes, hypertension

The FDA weighs the risks of candy

Latigo launches with $135 million for Vertex

Medtronic CEO on promising devices for diabetes, hypertension

Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

explore

knowledge

focus